We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Polarean Imaging Plc | LSE:POLX | London | Ordinary Share | GB00BF3DT583 | ORD GBP0.00037 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.05 | -1.28% | 3.85 | 3.70 | 4.00 | 3.90 | 3.85 | 3.90 | 159,492 | 08:33:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Surgical,med Instr,apparatus | 1.03M | -13.91M | -0.0644 | -0.60 | 8.31M |
TIDMPOLX
RNS Number : 5605U
Polarean Imaging PLC
01 April 2019
1 April 2019
Polarean Imaging Plc
("Polarean" or the "Company")
Amphion Innovations plc - Pledge of Polarean shares
Polarean Imaging plc (AIM: POLX), the medical--imaging technology company, with a proprietary drug--device combination product for the magnetic resonance imaging (MRI) market, notes that its partner company Amphion Innovations plc ("Amphion"), has pledged its holding of 18,372,523 shares in Polarean as additional security against its loan facility with its debt provider (the "Lender").
Amphion has transferred the legal title to, but retains the beneficial interest in, the pledged shares in Polarean. In addition, the Lender has agreed to adhere to the terms of an orderly market agreement for the next 12 months with regards to the 18,372,523 Polarean shares.
The full announcement from Amphion is available here
http://www.rns-pdf.londonstockexchange.com/rns/5605U_1-2019-3-29.pdf
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com Richard Hullihen, Chief Executive Officer Via Walbrook PR Richard Morgan, Chairman SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470 David Hignell Lindsay Mair MC Services (European IR) Tel: +49 (0)89 210 2280 Raimund Gabriel Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001 Helen Cresswell Mob: +44 (0)7841 917 679
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution functional magnetic resonance imaging market.
The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.
The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate than current methods. The annual burden of pulmonary disease in the US is estimated to be over US $150 billion.
The Group is currently undertaking Phase III Non-Inferiority Clinical Trials for (129) Xe at Duke University and University of Virginia.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCDMGZFVLRGLZM
(END) Dow Jones Newswires
April 01, 2019 02:01 ET (06:01 GMT)
1 Year Polarean Imaging Chart |
1 Month Polarean Imaging Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions